Literature DB >> 7635778

Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa.

K A Mason1, L Milas, L J Peters.   

Abstract

PURPOSE: Paclitaxel is a potentially useful drug for augmenting the cytotoxic action of radiotherapy because it has independent cytotoxic activity against certain cancers and blocks cells in the radiosensitive mitotic phase of the cell cycle. However, all rapidly proliferating tissues, both normal and neoplastic, may be affected by this therapeutic strategy. The aim of this study was to define the in vivo response of rapidly dividing cells of the small bowel mucosa to paclitaxel given alone and in combination with radiation. METHODS AND MATERIALS: Mice were given single IV doses of 10 or 40 mg/kg paclitaxel or four doses of 10 mg/kg paclitaxel at 6, 12, or 24 h intervals. The kinetics of mitotic arrest and apoptosis in jejunal crypts of mice at 1-24 h after treatment were defined histologically. An in vivo stem cell microcolony assay was used to assess the radiosensitizing potential of paclitaxel when radiation was delivered at the peak of mitosis and at 24 h after drug treatment.
RESULTS: Paclitaxel blocked jejunal crypt cells in mitosis and induced apoptosis in a dose-dependent manner. Fractionating the paclitaxel dose over 1-4 days did not result in any greater accumulation of mitotically blocked cells than did a single dose. Mitosis peaked 2-4 h after paclitaxel and returned to near normal by 24 h. Apoptosis lagged several hours behind mitosis and peaked about 6 h later than mitosis. Despite these kinetic perturbations, there was little or no enhancement of radiation effect when single doses were delivered 2-4 h after paclitaxel administration. The maximum sensitizer enhancement ratio of 1.07 observed after a single paclitaxel dose of 40 mg/kg is consistent with independent crypt cell killing. Conversely, when radiation was given 24 h after paclitaxel, a significant protective effect of the drug (SER 0.89-0.92), most probably due to a regenerative overshoot induced by paclitaxel, was observed.
CONCLUSION: Stem cells of the jejunal mucosa determining radiation response were not radiosensitized by paclitaxel with the drug concentrations and dose delivery schedules used, although additive cytotoxicity was observed with the highest drug dose. A radioprotective effect was observed when radiation was given 24 h after paclitaxel administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635778     DOI: 10.1016/0360-3016(95)00037-Y

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Authors:  Chau Dang; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Patrick Morris; Alyson Abbruzzi; Carol Chen; Richard Steingart; Sujata Patil; Larry Norton; Eric Winer; Clifford Hudis
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  The effect of paclitaxel on the radiosensitivity of gynecological tumor cells.

Authors:  M Rave-Fränk; H Meden; A Jäschke; A Tänzer; O Boghun; R Fietkau
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

3.  Radiochemotherapy with paclitaxel: synchronization effects and the role of p53.

Authors:  F Wenz; S Greiner; F Germa; K Mayer; D Latz; K J Weber
Journal:  Strahlenther Onkol       Date:  1999-10       Impact factor: 3.621

4.  Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics.

Authors:  James D Orth; Rainer H Kohler; Floris Foijer; Peter K Sorger; Ralph Weissleder; Timothy J Mitchison
Journal:  Cancer Res       Date:  2011-06-28       Impact factor: 12.701

5.  G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy.

Authors:  Meihua Sui; Hongfang Zhang; Xiaoyun Di; Jinjia Chang; Youqing Shen; Weimin Fan
Journal:  Radiother Oncol       Date:  2012-06-09       Impact factor: 6.280

6.  Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer.

Authors:  Yonglian Zhu; José B Fariña; Syrus Meshack; Ana Santoveña; Shilpa Patel; Alexis Oliva; Matias Llabrés; Michael E Hodsdon; Carmen J Booth; Priscilla S Dannies
Journal:  Endocrine       Date:  2010-04-20       Impact factor: 3.633

7.  Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.

Authors:  Tyvin A Rich; Kathryn Winter; Howard Safran; John P Hoffman; Beth Erickson; Pramila R Anne; Robert J Myerson; Vivian Jm Cline-Burkhardt; Kimberly Perez; Christopher Willett
Journal:  Onco Targets Ther       Date:  2012-08-23       Impact factor: 4.147

8.  NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel.

Authors:  T Negishi; F Koizumi; H Uchino; J Kuroda; T Kawaguchi; S Naito; Y Matsumura
Journal:  Br J Cancer       Date:  2006-08-08       Impact factor: 7.640

9.  A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment.

Authors:  Nataša Anastasov; Ines Höfig; Vanja Radulović; Simon Ströbel; Michael Salomon; Jan Lichtenberg; Ina Rothenaigner; Kamyar Hadian; Jens M Kelm; Christian Thirion; Michael J Atkinson
Journal:  BMC Cancer       Date:  2015-06-10       Impact factor: 4.430

10.  Circulating microRNA and automated motion analysis as novel methods of assessing chemotherapy-induced peripheral neuropathy in mice.

Authors:  Qinghai Peng; Jordan Mechanic; Ahmed Shoieb; Ingrid D Pardo; Laura Schaevitz; Judith Fenyk-Melody; Allison Vitsky; Magalie Boucher; Chris Somps; Jon C Cook; Chang-Ning Liu
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.